Bavarian Nordic in vaccine deal for fever virus

Danish pharmaceutical company Bavarian Nordic has received approval from US health authorities for its chikungunya virus vaccine. The European Medicines Agency’s committee also recommended approval in Europe. To widen vaccine access, Bavarian Nordic partnered with Indian company Biological E. Limited, allowing the production of the vaccine in low and middle-income countries and increasing overall capacity. CEO Paul Chaplin emphasizes the necessity to meet the growing need for chikungunya prevention, especially in endemic areas. While Bavarian Nordic will still manage production and sales in Western markets, the virus, which causes fever, joint pain, and rash, is primarily spread by mosquitoes in tropical regions and can occasionally lead to chronic pain or rare fatalities.